Treatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development

Journal Title: Iranian Journal of Blood and Cancer - Year 2013, Vol 5, Issue 3

Abstract

Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozogamicin has been used to induce remission in relapsed patients. Report of the case: Here, we report the first Iranian child, an 8-year-old boy, with refractory acute myeloid who was treated with gemtuzumab ozogamicin. Unfortunately, remission was not achieved and the patient died of neutropenia and septic shock. Conclusion: Gemtuzumab ozogamicin therapy in our case was not successful in achieving remission. It could be due to longstanding chemotherapy and its detrimental effects on bone marrow of the patient. Further controlled studies are necessary to learn more about efficacy and safety of this new treatment. Keywords: Childhood acute myeloid leukemia, refractory, treatment, gemtuzumab ozogamicin

Authors and Affiliations

Samin Alavi, Mohammad Taghi Arzanian

Keywords

Related Articles

Neuroblastoma Associated with Bilateral Ptosis: Report of a Rare Condition

Neuroblastoma is a common tumor in pediatric cancer and which might present with usual or unusual clinical features. One of the rare clinical finding of neuroblastoma is paraneoplastic syndromes. We report a two year-old...

Malignant Hypertension Associated with Rhabdomyosarcoma

The Hypertension is divided into two types: primary and secondary. the secondary type, is particularly due to renal and arterial origin and is mostly seen. In children the Secondary hypertension caused by malignancies is...

Methylation Status of SOX17 and RUNX3 Genes in Acute Leukemia

Background: Several studies have examined the presence of DNA methylation of CpG islands in leukemia. Methylation of SOX17 and RUNX3 genes may play a role in leukemogenesis through silencing tumor suppressor genes. We in...

Download PDF file
  • EP ID EP365842
  • DOI -
  • Views 91
  • Downloads 0

How To Cite

Samin Alavi, Mohammad Taghi Arzanian (2013). Treatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development. Iranian Journal of Blood and Cancer, 5(3), 115-120. https://europub.co.uk/articles/-A-365842